Cybin Inc. (NASDAQ:HELP – Get Free Report) insider Eric So bought 100,000 shares of the business’s stock in a transaction dated Friday, September 4th. The stock was bought at an average cost of $12.09 per share, for a total transaction of $1,209,000.00. Following the completion of the purchase, the insider owned 4,365,014 shares of the company’s stock, valued at approximately $52,773,019.26. The trade was a 2.34% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.
Cybin Stock Performance
Shares of NASDAQ HELP opened at $13.68 on Thursday. The firm’s 50 day moving average price is $9.70 and its 200-day moving average price is $6.81. Cybin Inc. has a 52-week low of $3.76 and a 52-week high of $14.35. The company has a market cap of $1.03 billion, a PE ratio of -4.53 and a beta of 0.63.
Cybin (NASDAQ:HELP – Get Free Report) last announced its quarterly earnings data on Friday, August 14th. The company reported ($0.91) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.11). On average, analysts forecast that Cybin Inc. will post -2.95 earnings per share for the current fiscal year.
Institutional Trading of Cybin
Analyst Upgrades and Downgrades
Several brokerages recently commented on HELP. Wall Street Zen raised Cybin from a “strong sell” rating to a “sell” rating in a report on Saturday, August 29th. TD Cowen increased their price objective on shares of Cybin from $8.00 to $62.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Finally, Wells Fargo & Company began coverage on Cybin in a research report on Monday, July 27th. They set an “overweight” rating and a $16.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $48.60.
View Our Latest Analysis on Cybin
Cybin Company Profile
Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.
The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.
Featured Stories
- Five stocks we like better than Cybin
- Qualcomm’s Data Center Bet Looks More Real After Amazon’s AI Deal
- GE Aerospace’s $11.75B Deal Puts Howmet Aerospace in Focus
- Casey’s Post-Earnings Drop May Give Investors a Better Entry Into a Quality Retailer
- Sovereign AI: Palantir and Nebius Cut the Cloud Cord
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
